James Woodrow, MD
Pulmonary Disease · Denver, CONPI 1033134622
Payments from drug & device makers
Across 32 payments — averaging $32.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$222
- Inari Medical, Inc.$172
- Abiomed$152
- Baxter Healthcare$115
- Advanced Respiratory, Inc$85
- AstraZeneca$62
- plus $234 from 8 others
What the payments were for
- Food & beverage$1,041100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $222 |
| Inari Medical, Inc. | 1 | $172 |
| Abiomed | 1 | $152 |
| Baxter Healthcare | 2 | $115 |
| Advanced Respiratory, Inc | 2 | $85 |
| AstraZeneca | 4 | $62 |
| Mylan Specialty L.p. | 3 | $55 |
| Boehringer Ingelheim | 2 | $48 |
| Grifols USA, LLC | 2 | $34 |
| Edwards Lifesciences | 1 | $32 |
| Kaleo, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Olympus America Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,041 in reported general payments places this provider in the 50th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 159 | $167,215 |
| Dupixent PenDupilumab | 38 | $141,039 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 157 | $131,543 |
| Spiriva RespimatTiotropium Bromide | 129 | $128,666 |
| NucalaMepolizumab | 27 | $107,813 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 104 | $80,657 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 124 | $76,945 |
| Dupixent SyringeDupilumab | 16 | $69,263 |
| SymbicortBudesonide/Formoterol Fumarate | 139 | $51,359 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $43,304 |
| Incruse ElliptaUmeclidinium Bromide | 73 | $42,329 |
| Spiriva HandihalerTiotropium Bromide | 41 | $33,630 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $33,198 |
| DuleraMometasone/Formoterol | 53 | $31,313 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 48 | $29,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $222 | $445,546475 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $62 | $212,309344 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $48 | $209,323233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Denver
- Michael WechslerDenver$3.6M
- Jennifer Taylor CousarDenver$1.4M
- Evans Fernandez PerezDenver$1.3M
- Ronald BalkissoonDenver$1.2M
- Jeffrey SwigrisDenver$845K
- Joshua SolomonDenver$705K
- Marjorie GeorgeDenver$645K
- Charles DaleyDenver$591K
- Michael MohningDenver$588K
- James CrapoDenver$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.